Publication of Annual Report and Notice of AGM

RNS Number : 0976E

BiVictriX Therapeutics PLC

09 March 2022

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company" or "the Group")

Publication of Annual Report and Notice of AGM

Alderley Park, 9 March 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that its annual report and financial statements for the year ended 31 December 2021 ("Annual Report and Accounts") are available for download on the Company's website at  https://www.bivictrix.com/investor-centre; and confirms the date for its Annual General Meeting ("AGM").

The Annual Report and Accounts will be mailed to shareholders, who have elected to opt out on receiving electronic communications, later today.

The Company will hold its AGM on Thursday, 31 March 2022 at 12:00pm GMT at the Company' registered office, Mereside Alderley Park, Alderley Edge, Manchester, SK10 4TG.

-Ends-

For more information, please contact:

BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman	Email: [e-mail]
SP Angel Corporate Finance LLP (NOMAD and Broker)	Tel: [phone]
David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Melissa Gardiner, Genevieve Wilson, Alex Gunter	Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of solid tumour and haematological cancer indications. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com  

 

END

 

 

MSCBRGDXBUGDGDI